期刊文献+

APO A-I与眼部疾病关系的研究进展

Advanced study on relationship of APO A-I and eye diseases
下载PDF
导出
摘要 载脂蛋白A-I(apolipoprotein A-I,APO A-I)作为高密度脂蛋白的重要组成部分,具有维持高密度脂蛋白结构稳定、参与胆固醇逆转运、抗炎和抗氧化的作用。APO A-I水平异常会导致一系列疾病,如:心肌梗死、阿尔茨海默病、遗传性淀粉样变性等。近来研究发现,APO A-I的水平与糖尿病视网膜病变、年龄相关性黄斑变性等眼科疾病密切相关。本文就APO A-I与眼部疾病关系的研究现状进行综述。 Apolipoprotein A-I (APO A-I; is the most important segment of high- density lipoprotein (HDL), its roles includes possessing structural stability to maintain the structural integrity of HDL,inhibiting atherosclerosis by reversing cholesterol trans- port, playing anti-inflammatory and protecting against oxidative stress. The abnormal level of APO A-I has been identified as a risk factor for some diseases, such as acute myocardial infarction,Alzheimer' s disease ,heritage amyloidosis and some eye diseases, et al, Recently,the research shows the abnormal level of APO A-I is obviously correlated with diabetic retinopathy, age-related macular degeneration. This article reviews the re- cent advances in relationship of APO A-I and eye diseases.
出处 《眼科新进展》 CAS 北大核心 2013年第1期88-90,共3页 Recent Advances in Ophthalmology
基金 国家自然科学基金资助(编号:81271046) 北京市自然科学基金资助(编号:7042020)~~
关键词 载脂蛋白A—I 生理功能 眼部疾病 apolipoprotein A-I physiological function eye diseases
  • 相关文献

参考文献31

  • 1Henkhaus RS,Dodani S,Manzardo AM,Butler MG. APOA1 gene polymorphisms in the South Asian immigrant population in the United States[J].INDIAN JOURNAL OF HUMAN GENETICS,2011,(03):194-200.
  • 2Weers PM,Patel AB,Wan LC,Guigard E,Kay CM,Hafiane A. Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation[J].Journal of Lipid Research,2011,(01):35-44.
  • 3Eriksson M,Sch(o)nland S,Yumlu S,Hegenbart U von Hutten H Gioeva Z. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens:identification of three novel mutations in the APOA1 gene[J].Journal of Molecular Diagnostics,2009,(03):257-262.
  • 4Funke H,von Eckardstein A,Pritchard PH,Karas M Albers JJ Assmann G. A ffameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency,partial lecithin:cholesterol-acyltransferase deficiency,and corneal opacities[J].Journal of Clinical Investigation,1991,(01):371-376.
  • 5Nyunt AK,Ishida Y,Yu Y,Shimada S. Topical apolipoprotein A-1 may have a beneficial effect on the corneal epithelium in a mouse model of dry eye:a pilot study[J].Eye and Contact Lens,2008,(05):287-292.
  • 6Kawai S,Nakajima T,Hokari S,Komoda T,Kawai K. Apolipoprotein A-I concentration in tears in diabetic retinopathy[J].Annals of Clinical Biochemistry,2002,(01):56-61.
  • 7Kurumada S,Onishi A,Imai H,Ishii K,Kobayashi T,Sato SB. Stage-specific association of apolipoprotein A-I and E in developing mouse retina[J].Investigative Ophthalmology & Visual Science,2007,(04):1815-1823.
  • 8Li CM,Clark ME,Chimento MF,Curcio CA. Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression[J].Investigative Ophthalmology & Visual Science,2006,(07):3119-3128.
  • 9张旭,高昆,张海涛,高翔,葛文平,张小娟,张连峰,董伟.人载脂蛋白A1基因转基因小鼠的建立[J].中国实验动物学报,2011,19(6):461-464. 被引量:5
  • 10Ory DS,Schaffer JE. ApoA-1 in diabetes:damaged goods[J].Diabetes,2010,(10):2358-2359.

二级参考文献21

  • 1贾兴旺,田亚平,董振南,周和平.冠心病患者血脂及载脂蛋白水平的关系[J].军医进修学院学报,2007,28(1):66-67. 被引量:10
  • 2Forrester JS,Shah PK.Emerging strategies for increasing high density lipoprotein[J].Am J Cardiol,2006,98 (11):1542-1549.
  • 3Barter PJ,Kastelein JJ.Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease[J].J Ant Coll Cardiol,2006,47(3):492-499.
  • 4Brown BG,Zhao XQ,Chait A,et al.Simvastatin and niacin,antioxidant vitamins,or the combination for the prevention of coronary disease[J].N Engl J Med,2001,345 (22):1583-1592.
  • 5Robins SJ,Collins D,Wittes JT,et al.Relation of gemfibrozil treatment and lipid levels with major coronary events:VA-HIT:a randomized controlled trial[J].JAMA,2001,285 (12):1585-1591.
  • 6Grundy SM,Cleeman JI,Daniels SR,et al.Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart,Lung,and Blood Institute Scientific Statement[J].Circulation,2005,112 (17):2735-2752.
  • 7Buse JB,Ginsberg HN,Bakris GL,et al.Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement from the American Heart Association and the American Diabetes Association[J].Circulation,2007,115 (I):114-126.
  • 8Brunzell JD,Davidson M.,Furberg CD,et al.Lipoprotein management in patients with cardiometabolic risk:consensus statement from the American Diabetes Association and the American College of Cardiology Foundation[J].Diabetes Care,2008,31(4):811-822.
  • 9Li X,Chyu KY,Faria Neto JR,et al.Differential effects of Apo lipoprotein A1 mimetic peptide on evolving and established atherosclerosis in Apo lipoprotein E null mice[J].Circulation,2004,110(12):1701-1705.
  • 10Nissen SE,Tsunoda T,Tuzcu EM,et al.Effect of recombinant APOAI Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial[J].JAMA,2003,90 (17):2292-3000.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部